IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies: psoriatic arthritis and ankylosing spondylitis. 
EFFECTS ON TARGETS
Inhibit IL-17-induced upregulation of proinflammatory cytokines and chemokines, particularly on epithelial and mesenchymal cells. 
